ArriVent BioPharma Financial Statements
NASDAQ: AVBPHealthcareBiotechnologyUSD
16.73+0.02 (+0.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma revenue and earnings
ArriVent BioPharma reported a net loss of $166.3 million, compared with a loss of $80.5 million a year earlier. Diluted earnings per share came in at -$4.32.
Summary generated from market data by MetaCap's automated system. Methodology
ArriVent BioPharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Operating Expenses | 177.53M | 94.31M | 74.59M |
| Research & Development | 153.35M | 79.00M | 64.88M |
| Operating Income | -177.53M | -94.31M | -74.59M |
| Net Income | -166.31M | -80.49M | -69.33M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -4.32 | -2.56 | -32.38 |
| EPS (Diluted) | -4.32 | -2.56 | -32.38 |
| Shares Outstanding (Basic) | 38.46M | 31.47M | 2.14M |
| Shares Outstanding (Diluted) | 38.46M | 31.47M | 2.14M |
| EBITDA | -180.56M | — | — |
This table shows 3 annual periods of ArriVent BioPharma's income statement, from FY 2025 back to FY 2023, across 9 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow AVBP's reporting calendar. What is a income statement?